NPWT

ExtriCARE USA Highlights Mission and Product Innovations in NPWT

Retrieved on: 
Thursday, February 22, 2024

PHILADELPHIA, Feb. 22, 2024 /PRNewswire/ -- ExtriCARE USA, an innovator in the Negative Pressure Wound Therapy (NPWT) industry, is proud to present pivotal updates for 2024, showcasing significant advancements in its ExtriCARE product line and the broader NPWT market.

Key Points: 
  • PHILADELPHIA, Feb. 22, 2024 /PRNewswire/ -- ExtriCARE USA, an innovator in the Negative Pressure Wound Therapy (NPWT) industry, is proud to present pivotal updates for 2024, showcasing significant advancements in its ExtriCARE product line and the broader NPWT market.
  • He presents ExtriCARE's latest contributions to NPWT, emphasizing the enhancements made to the ExtriCARE product line.
  • ExtriCARE USA invites the industry to view the video and join in their mission to advance wound care.
  • For detailed information about ExtriCARE USA and the ExtriCARE product line, please visit www.extriCAREusa.com or call 877.312.NPWT (6798).

Lion Street Medical Completes Acquisition of Pensar Medical

Retrieved on: 
Monday, January 29, 2024

HOUSTON, Jan. 29, 2024 /PRNewswire/ -- Lion Street Medical, LLC is pleased to announce the successful acquisition of Pensar Medical , LLC, a prominent medical device company specializing in wound care.

Key Points: 
  • HOUSTON, Jan. 29, 2024 /PRNewswire/ -- Lion Street Medical, LLC is pleased to announce the successful acquisition of Pensar Medical , LLC, a prominent medical device company specializing in wound care.
  • The acquisition, finalized in October 2023, brings new leadership to the trusted Pensar Medical and WoundPro brands.
  • Founded in 2012, Pensar Medical specializes in cutting-edge Negative Pressure Wound Therapy (NPWT) systems, including WoundPro , which boasts the industry's most powerful and durable pump, and MicroDoc , a disposable unit for single-use NPWT (sNPWT).
  • "We see a complete product portfolio for NPWT at Pensar," said Jason Bandy, who led the acquisition and will join as Pensar Medical's CEO.

Europe Negative Pressure Wound Therapy Market Insights Report 2023-2028: Market to Grow by $290 Million - Focus on Germany, France, UK, Italy, and Spain - ResearchAndMarkets.com

Retrieved on: 
Monday, November 20, 2023

The "Europe Negative Pressure Wound Therapy Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Negative Pressure Wound Therapy Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The European negative pressure wound therapy (NPWT) market is projected to reach a value of $880 million by 2028 from $590 million in 2022, growing at a CAGR of 6.9%
    This report provides an in-depth analysis of the complete Europe NPWT market.
  • One of the major reasons for the lower adoption of NPWT products in the market is the need for reimbursement in some European countries.
  • Constant product launches in the market from key vendors to gain market share is included.

Advanced wound care market to grow by USD 4.02 million from 2022 to 2027|3M Co., 4L Health Co. Ltd., Anika Therapeutics Inc., Cardinal Health Inc., Carilex Medical Inc. and more among the key companies - Technavio

Retrieved on: 
Thursday, November 9, 2023

The global advanced wound care market is fragmented, with the presence of several global as well as regional vendors.

Key Points: 
  • The global advanced wound care market is fragmented, with the presence of several global as well as regional vendors.
  • 3M Co. - This company offers various products under its wound care segment, such as wound care dressings, compression systems and wraps, medical tapes, wound cleansers, wound closure, barriers, creams, and lotions.
  • By geography, the global advanced wound care market is segmented into North America, Europe, Asia, and Rest of World (ROW).
  • The increasing use of telemedicine in wound care treatments is an emerging advanced wound care market trend.

InfuSystem Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023

InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the third quarter ended September 30, 2023.
  • The financial results of our third quarter represent the seventh consecutive quarter with record revenue, which we believe reflect the fundamental strength of our business.
  • Gross profit for the third quarter of 2023 of $16.2 million increased slightly compared to the third quarter of 2022.
  • The Company will conduct a conference call for all interested investors on Tuesday, November 7, 2023, at 9:00 a.m. Eastern Time to discuss its third quarter 2023 financial results.

Medela Announces Transition of Wound Care Business, Creating a New Company Dedicated to Wound Therapy Solutions

Retrieved on: 
Friday, November 3, 2023

This new standalone wound care company will continue to provide wound care solutions powered by Medela’s medical vacuum technology including Medela’s Negative Pressure Wound Therapy (NPWT) line of products and services.

Key Points: 
  • This new standalone wound care company will continue to provide wound care solutions powered by Medela’s medical vacuum technology including Medela’s Negative Pressure Wound Therapy (NPWT) line of products and services.
  • Effective December 1, Jeff Castillo will transition from Executive Vice President of Medela Americas to lead the new wound care company as CEO.
  • Given this experience as well as his industry expertise in the wound care market, including the NPWT portfolio, Jeff is the ideal executive to lead the new standalone wound care company.
  • Medela is dedicated to ensuring a seamless transition for customers to the new wound care company.

Medela Expands Negative Pressure Wound Therapy Product Solutions with New Integrated Dressing

Retrieved on: 
Tuesday, August 15, 2023

The Invia® Integrated Dressing is indicated for all wound types, including closed surgical incision, and can be used in the hospital or home setting, for up to seven days.

Key Points: 
  • The Invia® Integrated Dressing is indicated for all wound types, including closed surgical incision, and can be used in the hospital or home setting, for up to seven days.
  • “We are thrilled to support the needs of our customers across the USA by introducing our Integrated Dressing,” explains Annette Brüls, CEO of Medela.
  • The Integrated Dressing is a ‘peel-and-stick’ adhesive, comprised of a three-layer fluid handling pad that features a skin-friendly silicone adhesive border.
  • To learn more about Medela’s complete negative wound pressure therapy system, visit medelahealthcare.com or fill out the online form to receive information, or visit the Medela booth at the SAWC Fall Conference in November in Las Vegas.

InfuSystem Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 3, 2023

InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the second quarter ended June 30, 2023.
  • Richard DiIorio, chief executive officer of InfuSystem, said, “I am extremely pleased with the results of the second quarter, which reflect the sixth consecutive quarter with record revenues.
  • Gross profit of $16.4 million for the second quarter of 2023 increased $1.5 million, or 10.3%, from $14.9 million for the second quarter of 2022.
  • The Company will conduct a conference call for all interested investors on Thursday, August 3, 2023, at 9:00 a.m. Eastern Time to discuss its second quarter 2023 financial results.

United States Negative Pressure Wound Therapy Market Insights 2023-2028: Rising Economic Burden of Wound Care in the US Spurs Demand for Advanced NPWT Products - ResearchAndMarkets.com

Retrieved on: 
Friday, July 21, 2023

The "US Negative Pressure Wound Therapy Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Negative Pressure Wound Therapy Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • Better reimbursement options drive the adoption of NPWT products in the market.
  • Hospitals and wound care clinics are major end-users of NPWT products and constitute for major market share.
  • Hospitals have a dedicated working staff to handle wound care, this is one of the major positive steps in the US wound care market.

The Most Positive Thing to Happen to Negative Pressure Wound Therapy

Retrieved on: 
Wednesday, June 7, 2023

OCEANSIDE, Calif., June 7, 2023 /PRNewswire/ -- AOTI Inc, the global leader in multi-modality topical wound oxygen, announced exciting news from ongoing WOCNext conference in Las Vegas, Nevada, where their game changing NEXA Negative Pressure Wound Therapy (NPWT) system made its official USA debut.

Key Points: 
  • The unique NEXA NPWT system is an incredibly flexible platform that is simple to use, silent, portable and affordable.
  • NEXA seamlessly combines the simplicity of disposable NPWT with the performance features of more traditional durable NPWT technology platforms.
  • AOTI's unique NEXA NPWT and Topical Wound Oxygen (TWO2) therapy are unlike any other treatment approaches.
  • 2 Reduced Hospitalizations and Amputations in Patients with Diabetic Foot Ulcers Treated with Cyclical Pressurized Topical Wound Oxygen Therapy: Real-World Outcomes; Jessica Izhakoff Yellin, et al; Advances in Wound Care 2022; http://doi.org/10.1089/wound.2021.0118